ADMA Biologics Inc (ADMA) financial statements (2020 and earlier)

Company profile

Business Address C/O ADMA BIOLOGICS, INC.
RAMSEY, NJ 07446
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments27487417234255
Cash and cash equivalents27487417234255
Receivables3751144
Inventory, net of allowances, customer advances and progress billings53402418191412
Inventory53402418191412
Other undisclosed current assets3222222
Total current assets:869710438456374
Noncurrent Assets
Property, plant and equipment32312930303030
Intangible assets, net (including goodwill)7777888
Goodwill4444444
Intangible assets, net (excluding goodwill)3344444
Deposits noncurrent assets3333211
Restricted cash and investments    444
Other undisclosed noncurrent assets    111
Total noncurrent assets:41403940444444
TOTAL ASSETS:1271381437889106118
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities14141089107
Accounts payable9975653
Accrued liabilities4533444
Deferred revenue0   
Debt0  0000
Other undisclosed current liabilities 100000
Total current liabilities:141510810107
Noncurrent Liabilities
Long-term debt and lease obligation68838242272626
Long-term debt, excluding current maturities68838241262626
Capital lease obligations1000
Liabilities, other than long-term debt172215151515
Deferred revenue222 
Due to related parties15  15151515
Other liabilities0000000
Other undisclosed noncurrent liabilities1112181818
Total noncurrent liabilities:87878660595959
Total liabilities:1011029668696966
Stockholders' equity
Stockholders' equity attributable to parent26364710203752
Common stock0000000
Additional paid in capital291290290240236236235
Accumulated deficit(265)(254)(243)(230)(216)(198)(183)
Total stockholders' equity:26364710203752
TOTAL LIABILITIES AND EQUITY:1271381437889106118

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Revenues12774445
Cost of revenue(12)(8)(10)(9)(11)(9)(10)
Gross profit:0(1)(4)(6)(7)(5)(5)
Operating expenses(20)(16)(18)(17)(21)(18)(18)
Other undisclosed operating income12810911910
Operating loss:(8)(9)(11)(13)(17)(14)(13)
Nonoperating income (expense)(3)(2)(2)0(1)(1)(1)
Other nonoperating expense  (2)(1)   
Interest and debt expense (3)(2)(10)(1)(1)(1)
Net loss:(11)(14)(15)(23)(19)(17)(16)
Other undisclosed net income attributable to parent 3210111
Net loss available to common stockholders, diluted:(11)(11)(13)(13)(18)(15)(15)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(11)(14)(15)(23)(19)(17)(16)
Comprehensive loss, net of tax, attributable to parent:(11)(14)(15)(23)(19)(17)(16)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: